Autologous hematopoietic stem cell transplantation (ASCT) is an important treatment for eligible patients with hematological malignancies, particularly multiple myeloma and relapsed lymphoma. Although advances in transplantation have improved outcomes, complications such as infections, febrile neutropenia, mucositis, delayed engraftment, organ toxicity, and relapse remain significant. This study aims to evaluate clinical outcomes and patient satisfaction after ASCT and identify factors associated with favorable or unfavorable transplant outcomes.
Adult patients (≥18 years) with a confirmed diagnosis of a hematological malignancy.
Patients undergoing their autologous hematopoietic stem cell transplantation (ASCT).
willingness to participate in the study
Patients undergoing allogeneic hematopoietic stem cell transplantation.
Patients with uncontrolled active infection or severe organ dysfunction that contraindicates transplantation.
Patients with incomplete clinical data or who withdraw consent during the study period.
All consecutive adult patients with hematological malignancies who underwent autologous hematopoietic stem cell transplantation at the Bone Marrow Transplantation Unit, Assiut University Hospitals, during the study period and fulfilled the eligibility criteria.
Cohort
Retrospective
Not listed
PFS
Clinical outcome of autologous hematopoietic stem cell transplantation, including overall survival (OS) and Progression-Free Survival (PFS).
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
